Az epidermális növekedési faktor receptorát célzó terápiák RAS paradoxona vastag- és végbélrákban
作者： József Tímár , István Láng , None
DOI: 10.1556/MONKOL.52.2008.2.7
关键词: Panitumumab 、 Molecular biology 、 Antibody therapy 、 Medicine
摘要: Absztrakt A vastag- es vegbelrak karcinogenezise soran a korai adenomakban az esetek kozel feleben K-RAS-, ennel ritkabban B-RAF-mutacio alakul ki. K-RAS-mutans daganatok inkabb ferfiakban alakulnak ki, mig B-RAF-mutans tumorok nőkre jellemzőek e genek mutacioja fuggetlen mikroszatellita-statusztol. Az epidermalis novekedesi faktor receptoranak (EGFR) valtozo mertekű expresszioja vegbelrakok dontő hanyadaban kimutathato; maga gen nem mutalt, amplifikacioja igen ritka, gyakrabban megfelelő kromoszoma poliszomiaja miatt fokozott kopiaszam. Ez kepezte alapjat anti-EGFR antitest-terapiak bevezetesenek kezelesebe. E terapiak indikaciojanak sokaig EGFR feherje legalabb minimalis szintű jelentette. ket antitest-terapia kemoterapia-rezisztens kolorektalis rakok monoterapiaja eseten hasonlo (kb. 10%) objektiv tumorvalaszt eredmenyez, mely daganat EGFR-statuszatol. panitumumab eseteben feny derult azonban ...
sci-hub.st 参考文章(53)
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
Toshio Kuwai, Toru Nakamura, Takamitsu Sasaki, Sun-Jin Kim, Dominic Fan, Gabriel J. Villares, Maya Zigler, Hua Wang, Menashe Bar-Eli, Robert S. Kerbel, Isaiah J. Fidler, Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. ,vol. 10, pp. 489- 500 ,(2008) , 10.1593/NEO.08200
Mace L. Rothenberg, John V. Cox, Russell F. DeVore, John D. Hainsworth, Richard Pazdur, Saul E. Rivkin, John S. Macdonald, Charles E. Geyer, John Sandbach, Daniel L. Wolf, J. Scott Mohrland, Gary L. Elfring, Langdon L. Miller, Daniel D. Von Hoff, A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. ,vol. 85, pp. 786- 795 ,(1999) , 10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9
Paul M. Harari, Gregory W. Allen, James A. Bonner, Biology of Interactions: Antiepidermal Growth Factor Receptor Agents Journal of Clinical Oncology. ,vol. 25, pp. 4057- 4065 ,(2007) , 10.1200/JCO.2007.11.8984
T André, C Louvet, F Maindrault-Goebel, C Couteau, M Mabro, J.P Lotz, V Gilles-Amar, M Krulik, E Carola, V Izrael, A de Gramont, CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer European Journal of Cancer. ,vol. 35, pp. 1343- 1347 ,(1999) , 10.1016/S0959-8049(99)00150-1
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
O. A. Press, W. Zhang, M. A. Gordon, D. Yang, G. Lurje, S. Iqbal, A. El-Khoueiry, H.-J. Lenz, Gender-Related Survival Differences Associated with EGFR Polymorphisms in Metastatic Colon Cancer Cancer Research. ,vol. 68, pp. 3037- 3042 ,(2008) , 10.1158/0008-5472.CAN-07-2718
Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2
T Sauer, M G Guren, T Noren, S Dueland, Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti‐EGFR therapy? Histopathology. ,vol. 47, pp. 560- 564 ,(2005) , 10.1111/J.1365-2559.2005.02252.X
Kenneth A Foon, Xiao-Dong Yang, Louis M Weiner, Arie S Belldegrun, Robert A Figlin, Jeffrey Crawford, Eric K Rowinsky, Janice P Dutcher, Nicholas J Vogelzang, Jared Gollub, John A Thompson, Garry Schwartz, Ronald M Bukowski, Lorin K Roskos, Gisela M Schwab, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody International Journal of Radiation Oncology Biology Physics. ,vol. 58, pp. 984- 990 ,(2004) , 10.1016/J.IJROBP.2003.09.098